binding. In order to determine the requirement of these ( Figures 4C and 4D) . The AB double mutant was also tested to determine the activity of the enhancer conMad/Medea binding sites for Race activation in vivo, these mutations were engineered into the Race entaining only the higher-affinity site C. This enhancer can only activate patchy lacZ expression in the presumptive hancer, which was tested using a lacZ reporter assay in transgenic embryos. Mutation of binding site A has amnioserosa, similar to the B m and C m enhancers ( Figure  4F ). Mutation of all three Mad/Medea binding sites relittle effect on lacZ expression driven by the mutated enhancer when compared to the wild-type enhancer sults in a complete loss of lacZ staining in the developing amnioserosa ( Figure 4E ). The same result is obtained in (Figure 4B, cf. with 4A) . In contrast, mutation of the Mad/ Medea binding sites B or C disrupts lacZ expression so transgenic embryos in which the enhancer has all three binding sites deleted (data not shown). These results that it becomes patchy along the anterior-posterior axis 
Discussion mutant embryos [8, 9], demonstrating that Brk repression is not a major contributor to the establishment of these type II threshold responses. Molecular Mechanism of Dpp Threshold Responses
Based on the results presented here, we predict that at least some type II thresholds that are expressed in The embryonic dorsal ectoderm is subdivided into distinct cell types by the Dpp/Scw gradient through the broader patterns than that directed by Race e will depend on yet higher enhancer affinity for Smads. These enactivation of at least three different thresholds of gene activity [8]. The extracellular Dpp/Scw gradient leads to a peak of nuclear Mad and Medea in the presumptive amnioserosa of gastrulating embryos flanked by a narrow plateau of lower concentration [13, 20, 21], which correlates with the type I and II threshold responses, respectively. We have provided evidence that Mad and Medea directly activate the peak type I threshold Race in vivo. Furthermore, increasing the affinity of the Smad binding sites in the enhancer can alter the threshold response to the extracellular morphogen gradient (Figure 6) .
On the basis of these results, we suggest that the high nuclear Smad concentration at the dorsal midline is sufficient to occupy the Smad binding sites in the Race enhancer, two of which are low affinity, whereas the lower levels of nuclear Smads detected in the dorsomedial ectoderm are not. Increasing the affinity of the Smad sites in the Race e enhancer allows occupancy at lower Smad concentrations and hence a wider expression pattern characteristic of a type II threshold. Therefore, expression of Race is restricted to the presumptive 
